Abstract: The present invention relates to peptides, their use in the treatment, amelioration or prevention of chronically active autoimmune inflammation, in particular rheumatoid arthritis, and to pharmaceutical compositions comprising the same.

Abstract: The present invention relates to short cyclic peptides, their use in the treatment, amelioration or prevention of a disease caused by antibodies targeting the thyrotropin-TSH receptor (TSHR) in the thyroid gland, in particular Graves' disease and orbitopathy, and to pharmaceutical compositions comprising the same.

Abstract: The present invention relates to a cyclic peptide, its use in the treatment, amelioration or prevention of a disease caused by antibodies targeting the thyrotropin-TSH receptor (TSHR) in the thyroid gland, in particular Graves' disease and orbitopathy, and to pharmaceutical compositions comprising the same.

Abstract: The present invention relates to short cyclic peptides, their use in the treatment, amelioration or prevention of a disease caused by antibodies targeting the thyrotropin-TSH receptor (TSHR) in the thyroid gland, in particular Graves' disease and orbitopathy, and to pharmaceutical compositions comprising the same.

Abstract: A print head includes a capillary around an axis of symmetry for a liquid to be printed, the capillary adjoining at least one elastic element and having a nozzle opening which opens into a prechamber. The prechamber has an outlet opening aligned with the nozzle opening of the capillary in its axial orientation of the axis of symmetry and at least one inlet opening for a guide gas. The at least one elastic element forms a guide for the capillary in its axial orientation only. A feed for the liquid to be printed is provided in the capillary. A mechanical oscillation system is provided that includes the at least one elastic element and the capillary with the liquid contained therein. An actuator with a mechanical or magnetic force interaction with the oscillation system is further provided.

Abstract: The present invention relates to a fusion protein selectively binding collagen and having ectonucleotidase activity. The fusion protein comprises an amino acid sequence of the extracellular domain of glycoprotein VI fused via a first linker sequence to the N-terminus of an amino acid sequence of an Fc region, whereby the C-terminus of the Fc region is linked via a second linker sequence to an amino acid sequence of the extracellular domain of a CD39 protein. The fusion protein is useful in the treatment or prevention of cardiovascular disease or diabetes, such as in the treatment of acute atherothrombotic events with a favorable risk-benefit ratio.

Abstract: A print head includes a capillary around an axis of symmetry for a liquid to be printed, the capillary adjoining at least one elastic element and having a nozzle opening which opens into a prechamber. The prechamber has an outlet opening aligned with the nozzle opening of the capillary in its axial orientation of the axis of symmetry and at least one inlet opening for a guide gas. The at least one elastic element forms a guide for the capillary in its axial orientation only. A feed for the liquid to be printed is provided in the capillary. A mechanical oscillation system is provided that includes the at least one elastic element and the capillary with the liquid contained therein. An actuator with a mechanical or magnetic force interaction with the oscillation system is further provided.

Abstract: The present invention relates to a fusion protein selectively binding collagen and having ectonucleotidase activity. The fusion protein comprises an amino acid sequence of the extracellular domain of glycoprotein VI fused via a first linker sequence to the N-terminus of an amino acid sequence of an Fc region, whereby the C-terminus of the Fc region is linked via a second linker sequence to an amino acid sequence of the extracellular domain of a CD39 protein. The fusion protein is useful in the treatment or prevention of cardiovascular disease or diabetes, such as in the treatment of acute atherothrombotic events with a favorable risk-benefit ratio.

Abstract: The present invention relates to a cyclic peptide, its use in the treatment, amelioration or prevention of a disease caused by antibodies targeting the thyrotropin-TSH receptor (TSHR) in the thyroid gland, in particular Graves' disease and orbitopathy, and to pharmaceutical compositions comprising the same.

Abstract: The present disclosure relates to binding compounds/antibodies that bind to the second extracellular loop of the human ?1-adrenoreceptor (?1-AR-ECII) that are produced by/obtainable from a host cell/hybridoma with a deposit number selected from the group consisting of DSM ACC3121, DSM ACC3174, DSM ACC3175, DSM ACC3176 and DSM AC-C3177. The binding compounds/antibodies are particularly useful in determination of auto-anti-?1-AR antibodies in an in vitro cell based assay system in order to characterize and to identify auto-antibodies directed against the ?1-AR-ECII in a biological sample. Further aspects of the disclosure are nucleic acid molecules encoding said binding compounds/antibodies, vectors, host cells, methods for producing the binding compounds/antibodies of the disclosure as well as a kit comprising the binding compounds/antibodies of the present disclosure.

Abstract: The present disclosure relates to agents which interfere with the binding of GPVI to various components. Agents which interfere with GPVI interaction with one or both of fibronectin and vitronectin or sequences thereof are also disclosed. Methods of treating disorders or diseases which involve pathological, dysfunctional or non-pathological interaction of GPVI with fibronectin and/or vitronectin are included in the present disclosure. The invention also relates to uses of agents for the prevention or treatment of disorders arising from blood platelet adhesion and aggregation.

Abstract: The present invention provides a fusion protein comprising (1) the extracellular domain of glycoprotein VI or a variant thereof that is functional for binding to collagen and (b) the Fc domain of the immunoglobulin or a function-conservative part thereof, characterized by a polypeptide chain having an amino acid sequence as shown in FIG. 7 and whereby the fusion protein is obtainable by a process which provides the fusion protein in the form of a specific dimer.

Abstract: The present invention provides a fusion protein comprising (a) the extracellular domain of glycoprotein VI or a variant thereof that is functional for binding to collagen and (b) the Fc domain of an immunoglobulin or a function-conservative part thereof, characterised by a polypeptide chain having an amino acid sequence as shown in FIG. 7 and whereby the fusion protein is obtainable by a process which provides the fusion protein in the form of a specific dimer.

Abstract: Mammals and myocardial mammal cells transformed with G protein coupled receptor EDG2 are presented for use in an animal model for heart failure.

Abstract: A 5H-Thiazolo[3,2]pyrimidine derivative or a salt thereof for use as a medicine, which is represented by the following formula (A): wherein R represents an optionally substituted phenyl or pyridyl group; R4 represents a hydroxyl group, an amino group, a straight chain or branched alkoxy group, a straight chain or branched alkyl group, a cycloalkyloxy group, an alkylamino group, a cycloalkylamino group, a dialkylamino group, R5 represents a hydrogen atom, a straight chain or branched alkyl group, R6 and R7, which may be the same or different represent a hydrogen atom, a halogen atom, a straight chain or branched alkyl group, a straight chain or branched alkoxy group, a straight chain or branched alkenyl group, a cycloalkyl group, an aryl group, X, Y, and Z which may be same or different represent a hydrogen atom, a halogen atom, a carboxyl group a nitro group, a cyano group, an alkyl group, an alkoxy group or an acyl group.

Abstract: The invention discloses use of peptide containing an essential ventricular myosin light chain type 1 (vMLC1) amino acid sequence, which is functional as cleavage site for caspase-3, in the screening for a compound for the treatment of chronic or acute cardiovascular disease. Further, screening methods for inhibitors of the caspase-3-mediated cleavage of vMLC1 are disclosed.

Abstract: The present invention provides a fusion protein comprising (1) the extracellular domain of glycoprotein VI or a variant thereof that is functional for binding to collagen and (b) the Fc domain of the immunoglobulin or a function-conservative part thereof, characterised by a polypeptide chain having an amino acid sequence as shown in FIG. 7 and whereby the fusion protein is obtainable by a process which provides the fusion protein in the form of a specific dimer.

Abstract: The present invention refers to a test system for the identification of a ligand for angiotension receptor like-1 (APJ receptor) comprising an APJ receptor or a functional variant thereof and a G?q or a G?l protein or a hybrid protein which is assembled from portions of different G proteins like G?q or G?l proteins, a method of screening an APJ receptor ligand using the test system, a method for producing a medicament, a method for diagnosis and prognosis of a heart disease and a kit usable for detection or prognosis of a heart disease.

Abstract: A composition is provided comprising patelets having a combination of the following modifications: a) a modification of the protein constituents of the platelets which is obtained or obtainable by genetic modification of platelet precursor cells; b) incorporation of a detectable label into said platelet; whereby the functions of modification a) and b) are mutually independent. Further, methods of determining platelet functions, notably aggregation and adhesion to endothelial cells are provided. Further, a novel method of preparing transgenic or modified platelets is provided.

Abstract: The present invention provides a fusion protein comprising (a) the extracellular domain of glycoprotein VI or a variant thereof that is functional for binding to collagen and (b) the Fc domain of an immunoglobulin or a function-conservative part thereof, characterised by a polypeptide chain having an amino acid sequence as shown in FIG. 7 and whereby the fusion protein is obtainable by a process which provides the fusion protein in the form of a specific dimer.